Clene Inc. CLNN
We take great care to ensure that the data presented and summarized in this overview for Clene Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLNN
View all-
Vanguard Group Inc Valley Forge, PA2.62MShares$15.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA922KShares$5.41 Million0.0% of portfolio
-
Scoggin Management LP New York, NY375KShares$2.2 Million0.05% of portfolio
-
Morgan Stanley New York, NY339KShares$1.99 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL273KShares$1.6 Million0.0% of portfolio
-
Csenge Advisory Group270KShares$1.58 Million0.01% of portfolio
-
Laird Norton Trust Company, LLC269KShares$1.58 Million0.01% of portfolio
-
Northern Trust Corp Chicago, IL230KShares$1.35 Million0.0% of portfolio
-
Group One Trading, L.P. Chicago, IL142KShares$835,8350.0% of portfolio
-
State Street Corp Boston, MA128KShares$751,6300.0% of portfolio
Latest Institutional Activity in CLNN
Top Purchases
Top Sells
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Insider Transactions at CLNN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
Alison Mosca |
BUY
Grant, award, or other acquisition
|
Indirect |
159,134
+33.14%
|
$636,536
$4.59 P/Share
|
Sep 30
2024
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
92,307
+17.2%
|
$369,228
$4.75 P/Share
|
Sep 30
2024
|
Robert Dee Etherington Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+19.94%
|
$40,000
$4.75 P/Share
|
Sep 30
2024
|
Mark Mortenson Chief Science Officer |
BUY
Open market or private purchase
|
Direct |
20,512
+41.47%
|
$82,048
$4.75 P/Share
|
Jul 29
2024
|
Robert Dee Etherington Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,320
+47.54%
|
$81,960
$3.0 P/Share
|
May 01
2024
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,000
-0.08%
|
$0
$0.4 P/Share
|
Apr 30
2024
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,000
-0.08%
|
$0
$0.42 P/Share
|
Apr 24
2024
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,000
-0.07%
|
$0
$0.33 P/Share
|
Apr 09
2024
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
22,500
-0.05%
|
$0
$0.39 P/Share
|
Nov 10
2023
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
250,002
+3.43%
|
$0
$0.41 P/Share
|
Jun 26
2023
|
John Henry Stevens |
BUY
Open market or private purchase
|
Direct |
316,455
+28.34%
|
$0
$0.8 P/Share
|
Jun 26
2023
|
Robert Dee Etherington Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
25,000
+50.0%
|
$0
$0.81 P/Share
|
Jun 16
2023
|
Chidozie Ugwumba |
BUY
Open market or private purchase
|
Indirect |
7,500,000
+36.55%
|
$0
$0.8 P/Share
|
Jun 16
2023
|
Alison Mosca |
BUY
Open market or private purchase
|
Indirect |
2,394,375
+42.51%
|
$0
$0.8 P/Share
|
Jun 16
2023
|
Jonathon Gay |
BUY
Open market or private purchase
|
Indirect |
105,625
+50.0%
|
$0
$0.8 P/Share
|
Jun 16
2023
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
1,500,000
+18.09%
|
$0
$0.8 P/Share
|
Nov 14
2022
|
Reed N Wilcox |
BUY
Exercise of conversion of derivative security
|
Direct |
174,912
+23.32%
|
$0
$0.15 P/Share
|
Nov 02
2022
|
Jonathon Gay |
BUY
Open market or private purchase
|
Indirect |
990,099
+31.48%
|
$990,099
$1.01 P/Share
|
Nov 02
2022
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
2,871,287
+35.17%
|
$2,871,287
$1.01 P/Share
|
Nov 02
2022
|
John Henry Stevens |
BUY
Open market or private purchase
|
Direct |
148,515
+23.49%
|
$148,515
$1.01 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 27.3K shares |
---|---|
Open market or private purchase | 373K shares |
Grant, award, or other acquisition | 159K shares |
Open market or private sale | 58.5K shares |
---|